After Big Pharma sparked interest in the US, Ablaze looks to bring radiopharmaceuticals overseas

Ablaze Pharmaceuticals emerged from stealth on Monday with a Vivo Capital and AdvanTech Capital-led Series A round and a licensing pact with Versant-backed RayzeBio. The goal? Introduce targeted radiopharmaceutical therapies (TRTs) to the Chinese market.